The Evolution of Brain Stimulation: How EXOMIND Builds on Nearly a Century of Neuroscience
From electroconvulsive therapy in 1938 to the invention of TMS in 1985 and the repetitive protocols used today, EXOMIND sits at the end of a long research lineage. Here is that history, what the trials actually show, and the honest limits of the evidence.
If you are having thoughts of suicide or self-harm, or you are in immediate distress, call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency room. Nothing in this article is emergency care or a substitute for it.
EXOMIND is not a new idea. It is the latest step in a scientific journey that began nearly 100 years ago, built on decades of research into how the brain regulates mood, behavior, motivation and emotional wellbeing. The line runs from the earliest attempts to influence brain activity in the 1930s, through the invention of transcranial magnetic stimulation in 1985, to the repetitive TMS protocols used today at practices like Camarillo Spine & Nerve Institute in Camarillo, CA. Understanding that history makes the technology far less mysterious.
Why the History Matters
When most people hear about EXOMIND for the first time, they often assume it is a completely new technology. Knowing that it sits at the end of a long research lineage changes how you evaluate it. The development of this modality reflects a broader shift in healthcare, from simply managing symptoms toward understanding and supporting the underlying systems that drive human function.
At Camarillo Spine & Nerve Institute, that philosophy feels familiar. Whether we are treating chronic pain, mobility limitations, neuropathy or mental wellness concerns, the focus remains the same: identify root causes, restore function and improve quality of life.
The Early Days of Neurostimulation
The story begins in 1938 with the development of electroconvulsive therapy, one of the earliest technologies designed to influence brain activity in patients suffering from severe psychiatric conditions. While effective in some circumstances, it was a blunt instrument by modern standards, and researchers continued searching for approaches that could stimulate the brain more precisely and more comfortably.
That search led to a major breakthrough in 1985, when researchers in Sheffield, England demonstrated transcranial magnetic stimulation in humans. For the first time, clinicians could influence brain activity using focused magnetic fields without surgery and without implanted devices. A coil held against the scalp produced a brief magnetic pulse, that pulse induced a small electrical current in the cortex beneath it, and the effect could be measured. This discovery laid the foundation for the technologies we use today.
Early TMS was largely a research and diagnostic tool. The step that turned it into a treatment was repetition: delivering pulses in trains rather than singly, which is where the term repetitive TMS, or rTMS, comes from.
From Experimental Research to Clinical Treatment
Over the following decades, researchers gained a deeper understanding of how specific regions of the brain influence mood, cognition and emotional regulation. As evidence accumulated, regulatory decisions followed. In 2008, a repetitive transcranial magnetic stimulation device received FDA clearance in the United States for the treatment of major depressive disorder in adults who had not responded adequately to antidepressant medication.
Clearances in the years since have extended TMS devices to further indications, with obsessive-compulsive disorder and smoking cessation among them, and researchers have studied applications including anxiety symptoms and disordered eating. Regulatory status differs by device, by indication and by country, and it changes over time, so it is always worth asking a provider exactly what applies to the specific device in front of you rather than assuming a general clearance covers everything.
The National Institute of Mental Health overview of brain stimulation therapies is a useful neutral reference on where each of these technologies currently sits.
What the Research Actually Shows, Including Its Limits
This is the part of the story that marketing usually skips, and it is the part patients deserve most.
The pivotal independent trial of daily left prefrontal rTMS for depression was published in 2010. In that sham-controlled randomized trial by George and colleagues in Archives of General Psychiatry, patients receiving active stimulation were significantly more likely to reach remission than those receiving a convincing sham, but the absolute remission rate in the active group was modest, in the region of one in seven during the blinded phase. The result was real, replicable and clearly better than sham. It was not a transformation for most participants.
Pooled evidence tells a similar story. A meta-analysis of randomized, double-blind, sham-controlled rTMS trials by Berlim and colleagues in Psychological Medicine found that roughly one in three patients responded to active high-frequency rTMS and roughly one in five achieved remission, compared with markedly lower rates on sham. Later work has refined the delivery, notably the finding that shorter theta-burst protocols appear to work about as well as the longer standard protocol, which made treatment far more practical to schedule.
Studies suggest, in other words, that rTMS helps a meaningful minority of people with depression more than a placebo procedure does. Many patients report improvement in mood, motivation and focus. Many others notice little. Anyone who promises more than that is going beyond the evidence.
The Development of EXOMIND
Building on this foundation, BTL, the company behind technologies such as EMSCULPT NEO and EMSELLA, invested in neurostimulation research and introduced EXOMIND as a platform designed to deliver repetitive transcranial magnetic stimulation. Patients at our practice often recognise the name, because the same manufacturer supplies the devices we use for core strengthening with Emsculpt Neo and for Emsella pelvic floor therapy.
What makes EXOMIND significant is not that it reinvents neurostimulation. Its significance comes from refining decades of scientific research into a modern, non-invasive patient experience that is comfortable and easy to integrate into everyday life. The underlying modality is rTMS, the same family of technology described above, with the same evidence base and the same honest limits. If you want the practical walkthrough rather than the history, our companion article on what EXOMIND is and how a drug-free mental wellness session works covers it in detail.
Who Is and Is Not a Candidate
A century of refinement has not made TMS suitable for everyone. Some exclusions are absolute, and they exist because the treatment works by generating a magnetic field close to the head.
- Ferromagnetic metal in or near the head, including certain clips, plates, fragments and implants
- Implanted electronic devices in or near the head
- Cochlear implants
- Deep brain stimulators
- Aneurysm clips
- A personal or family history of seizures, or medications and conditions that lower the seizure threshold
- Pregnancy, which warrants caution and usually exclusion pending obstetric input
Seizure is the most serious known risk of rTMS and is rare when established screening and dosing protocols are followed. The common effects are much milder: tenderness at the application site and a short-lived headache, both of which typically ease over the first several sessions. Candidacy is decided at a consultation, not over the phone, and part of that consultation is telling people honestly when this is not the right fit for them.
What a Session Involves Today
The contrast with 1938 is the clearest measure of how far the field has travelled. There is no anesthesia, no sedation, no induced seizure and nothing implanted. You sit upright in a chair, fully awake. The applicator is positioned against your head, and the device delivers pulses in short trains with pauses between them, producing a tapping sensation and an audible click. Sessions typically run under 30 minutes, there is no downtime, and you drive yourself home.
Like all rTMS, EXOMIND is delivered as a course of sessions rather than a single visit, and improvements, where they occur, tend to build gradually across that course. Your provider will explain the schedule that applies to you before you commit to anything.
How This Fits Alongside Psychiatric Care
EXOMIND complements psychiatric care, psychotherapy and prescribed medication. It does not replace any of them, and we do not claim it is superior to either therapy or medication.
Camarillo Spine & Nerve Institute is not a mental health provider. We do not diagnose psychiatric conditions and we do not prescribe psychiatric medication. Treatment is delivered under appropriate professional oversight and only after a consultation. Nobody should stop, reduce or change a prescribed medication because they have begun TMS or because they feel better on it, since stopping an antidepressant abruptly can cause discontinuation symptoms and relapse. Those decisions belong to the clinician who wrote the prescription. If you are weighing your options for depression and anxiety, the most realistic frame is a coordinated plan with several supports running at once.
Why Mental Wellness Matters at CSNI
At Camarillo Spine & Nerve Institute, we believe health cannot be divided into isolated categories. The brain influences how we think, move, recover, adapt and engage with the world around us. Likewise, chronic pain, reduced mobility, poor sleep and physical limitations often affect emotional wellbeing. We see these connections every day:
- Pain can reduce activity.
- Reduced activity can lead to deconditioning.
- Loss of strength and mobility can affect confidence and independence.
- Over time, emotional wellbeing may suffer as a result.
This is why our practice continues to expand beyond traditional models of care. Our mission is not simply symptom management. It is helping patients restore function, maintain resilience and improve quality of life through evidence-based, non-surgical solutions, which is the same thread running through our wider functional wellness services in Camarillo, CA.
Looking Forward
The history of neurostimulation reflects a larger story unfolding across healthcare. As our understanding of the brain continues to evolve, treatment approaches are becoming more precise, more personalized and more focused on helping people regain control of their lives. EXOMIND is part of that evolution.
For individuals living with depression, or looking for something to sit alongside medication-based treatment rather than instead of it, this modality represents an opportunity to benefit from decades of scientific progress. At CSNI, that is ultimately what every treatment is designed to support: helping people live more fully, move more freely and participate more completely in the lives they want to lead.
Frequently Asked Questions About Brain Stimulation and EXOMIND
Is TMS the same thing as electroconvulsive therapy?
No. They are separate technologies from different eras. Electroconvulsive therapy, developed in 1938, is performed under general anesthesia and deliberately induces a brief seizure. TMS, demonstrated in humans in 1985, uses focused magnetic pulses while the patient sits awake in a chair, with no anesthesia and no induced seizure. The side effect profiles are correspondingly different, with scalp tenderness and mild headache being the usual complaints after rTMS.
How well does rTMS actually work for depression?
Studies suggest it helps a meaningful minority of patients more than a sham procedure does. Pooled sham-controlled trial data indicate roughly one in three patients respond to active high-frequency rTMS and roughly one in five reach remission, with clearly lower rates on sham. That is a real effect, replicated across trials, but it is not a guarantee and not a cure. Individual response varies, and some people notice little change.
Has TMS been approved by the FDA?
A repetitive TMS device first received FDA clearance for major depressive disorder in adults in 2008, and further clearances have followed for other indications. Regulatory status varies by device, by indication and by country, and it changes over time, so ask your provider precisely what applies to the device being used in your treatment rather than relying on a general statement about the category.
Why did it take so long to go from invention to treatment?
The 1985 breakthrough produced a tool, not a therapy. Turning single pulses into a repeated treatment protocol required decades of work to identify which brain region to target, at what frequency and intensity, for how many sessions, and to establish safety limits. Large sham-controlled trials then had to demonstrate benefit over placebo, which is a slow process and the reason the first clearance did not arrive until 2008.
Who should not have TMS?
TMS is generally avoided in anyone with ferromagnetic metal or an implanted electronic device in or near the head, including cochlear implants, deep brain stimulators and aneurysm clips. A personal or family history of seizures calls for caution or exclusion, as does pregnancy. Screening at consultation covers implants, surgical history, head injury, seizure history and your full medication list, because some medications lower the seizure threshold.
Can I stop my antidepressant if EXOMIND helps?
Not without speaking to your prescriber first. EXOMIND complements prescribed medication and psychiatric care rather than replacing them, and stopping an antidepressant abruptly can cause discontinuation symptoms and relapse. Camarillo Spine & Nerve Institute does not prescribe or manage psychiatric medication, so any change to your prescription is a decision for the clinician who wrote it, not for us.
What should I do if I am in crisis right now?
Call or text 988 immediately to reach the Suicide and Crisis Lifeline, available 24 hours a day across the United States, or go to your nearest emergency room. Call 911 if someone is in immediate danger. A course of brain stimulation is scheduled care that builds over weeks and is never a substitute for urgent help, so please do not wait for an appointment with us if you are in distress now.
Book Your Consultation in Camarillo, CA
If the science interests you and you want to know whether it applies to your situation, the next step is a consultation rather than a commitment. We will review your history, screen you against the contraindications above and be straightforward if this is not the right fit. Read more about TMS therapy with Exomind, or get in touch with our Camarillo, CA office. Camarillo Spine & Nerve Institute has served Camarillo, Thousand Oaks, Oxnard, Ventura and the wider Ventura County area since 1994.
